Carefirst Blue Cross Blue Shield
Dr. Manuel Aran, MD
Be the first to review this provider!
Hialeah, FL
Call for new patient details
47 years of experience
Clinical Overview
Dr. Manuel Aran, MD works in Hialeah, FL as
Dr. Aran graduated from Autonomous University of Guadalajara School of Medicine in 1979. Dr. Aran's office is not accepting new patients at this time.
Dr. Aran also speaks French and Spanish.
COMPARE OTHER TOP Internal Medicine Doctors
Contrast Dr. Aran with other nearby specialists practicing at HCA Florida Mercy Hospital.
Make an appointment at HCA Florida Mercy Hospital today at (305) 330-1534.
Make an appointment at HCA Florida Mercy Hospital today at (305) 330-1534.
Dr. Tony Abbassi, MD
Learn More
Dr. Christina Rodriguez, MD
Learn More
Dr. Juan Prieto, MD
Learn More
Dr. Ariel Ramirez Navarro, MD
Learn More
Dr. Silvia Robalino, MD
Learn More
Dr. Karen Fernandez Espinal, MD
Learn More
These providers are on the medical staff of HCA Florida Mercy Hospital.
Advertisement
Insurance & Payment Information
* Please verify this information when scheduling an appointment.
-
-
Cigna
-
Blue Cross Blue Shield of Florida
-
United Healthcare
-
AvMed
-
Aetna
-
Medicare
Office Locations
-
Office2475 E 5th Ave, Hialeah, FL 33013
Patient Experience & Satisfaction
Be the first to leave a review
How likely are you to recommend Dr. Aran?
Step 1 of 3
Your review of Dr. Manuel Aran, MD
50 characters remaining
1000 characters remaining
Was this a Telehealth appointment?
(This will display with your review)
Your email is used to confirm your review and will NOT appear in the review.
This name will appear with your review. If left blank, we'll use "Anonymous".
RVO Health property, Medical News Today, is owned by RVO Health. Please review our terms of use for more.
Help other patients find the right care by sharing a few more details about your visit.
Last step! Confirm your email.
We've sent an email to
Once you confirm, you can close this window.
Thank you for your review!
Your review has been confirmed and will be published after verification.
Thank you for your review!
We've sent a confirmation email. Your review will appear after you confirm it.
Please allow up to 30 seconds for the email to arrive. Don't see it? Make sure to check your 'spam' and 'updates' folder. Once you've confirmed your review, you can close this window.
Medical Expertise & Background
Languages Spoken
French
Spanish
Specialties*
Orthopedic Sports Medicine
Internal Medicine
- *Medical News Today does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.
Common Patient Questions
Dr. Aran accepts CareFirst Blue Cross Blue Shield, Cigna, Blue Cross Blue Shield of Florida, UnitedHealthCare, AvMed and Aetna as well as many others. See all of the insurances Dr. Aran accepts here.
Dr. Aran's office is located at 2475 E 5th Ave Hialeah, FL 33013. Get a map and directions to Dr. Aran's office here.
Yes, Dr. Aran speaks French and Spanish. See Dr. Aran's profile on MedicalNewsToday for more information.
Dr. Aran does not have any reviews yet.
Dr. Aran has been practicing as an Internist for 47 years.
Education & Credentials
Medical Education
-
Autonomous University of Guadalajara School of Medicine
1979
Claim Your Profile
Are you Dr. Manuel Aran, MD?
Know Before You Go
Preventive care: what doctors want you to know
Preventive care can help identify current or future health and medical concerns before they become major.
Featured Stories
The FDA has approved Moderna's new mRNA flu vaccine for adults ages 50 years and older. Moderna expects the vaccine to be available in the United States for the 2026 to 2027 flu season.
A natural compound derived from plant foods containing a certain type of polyphenol may help improve heart function in people with heart failure, a study in animals and human tissue models has found.
Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug pembrolizumab significantly reduced the risk of melanoma recurrence in a phase 3 trial.
